Nektar Therapeutics
Biopharmaceutical company focused on discovery and development of novel biologic therapies that modulate immune system function. The organization advances programs from preclinical research through clinical development, emphasizes regulatory and clinical operations, and pursues strategic collaborations to translate immunology research (regulatory T cell, IL-2/IL-15, TNFR2, CSF1R pathways) into therapeutic candidates for autoimmune, inflammatory and oncology indications.
Industries
Nr. of Employees
medium (51-250)
Nektar Therapeutics
Patents
Combination of an IL-2RBETA-selective agonist and a long-acting IL-15 agonist
US-12233104-B2
View DetailsMulti-arm polymer conjugates of TLR agonist compounds and related immunotherapeutic treatment methods
US-12214045-B2
View Details
Combination of an IL-2RBETA-selective agonist and a long-acting IL-15 agonist
US-12233104-B2
View DetailsMulti-arm polymer conjugates of TLR agonist compounds and related immunotherapeutic treatment methods
US-12214045-B2
View DetailsProducts
Treg-targeting IL-2 receptor agonist biologic (clinical-stage)
A biologic designed to selectively agonize IL-2 receptors on regulatory T cells to increase Treg number and function; being evaluated clinically in autoimmune and inflammatory indications (e.g., atopic dermatitis, alopecia areata, type 1 diabetes).
TNFR2-targeting bivalent antibody agonist (preclinical to IND-enabled)
Bivalent antibody construct designed to selectively stimulate TNFR2 to promote tissue-specific regulatory T-cell activation and stability, intended for autoimmune indications; first-in-human study planned.
Engineered IL-15 receptor agonist for immuno-oncology combinations
Engineered IL-15 receptor agonist designed to expand and sustain NK and CD8+ T-cell populations, developed for combination with checkpoint inhibitors and cellular therapies to enhance anti-tumor immunity.
CSF1R agonist biologic for inflammation resolution (preclinical)
Biologic agonist of the CSF1 receptor designed to activate pathways of inflammation resolution by targeting tissue-resident macrophage biology; intended for acute and chronic inflammatory indications.
Treg-targeting IL-2 receptor agonist biologic (clinical-stage)
A biologic designed to selectively agonize IL-2 receptors on regulatory T cells to increase Treg number and function; being evaluated clinically in autoimmune and inflammatory indications (e.g., atopic dermatitis, alopecia areata, type 1 diabetes).
TNFR2-targeting bivalent antibody agonist (preclinical to IND-enabled)
Bivalent antibody construct designed to selectively stimulate TNFR2 to promote tissue-specific regulatory T-cell activation and stability, intended for autoimmune indications; first-in-human study planned.
Engineered IL-15 receptor agonist for immuno-oncology combinations
Engineered IL-15 receptor agonist designed to expand and sustain NK and CD8+ T-cell populations, developed for combination with checkpoint inhibitors and cellular therapies to enhance anti-tumor immunity.
CSF1R agonist biologic for inflammation resolution (preclinical)
Biologic agonist of the CSF1 receptor designed to activate pathways of inflammation resolution by targeting tissue-resident macrophage biology; intended for acute and chronic inflammatory indications.
Services
Collaborative development partnerships spanning preclinical research through late-stage development and commercialization support.
Management and operational support for global clinical trials including site oversight, patient recruitment and clinical compliance.
Collaborative development partnerships spanning preclinical research through late-stage development and commercialization support.
Management and operational support for global clinical trials including site oversight, patient recruitment and clinical compliance.
Expertise Areas
- Clinical trial management
- Immunology-focused drug discovery and translational research
- Biologics process development and manufacturing support
- Immuno-oncology combination strategies
Key Technologies
- Regulatory T-cell (Treg) modulation
- Interleukin-2 pathway agonist strategy
- Interleukin-15 receptor agonist engineering
- TNFR2-targeted antibody engineering
News & Updates
Company webcast for second quarter 2026 financial results.
Final results from the 16-week induction period of an international, double-blind, placebo-controlled, randomized phase 2b study published in The Lancet.
Company webcast for second quarter 2026 financial results.
Final results from the 16-week induction period of an international, double-blind, placebo-controlled, randomized phase 2b study published in The Lancet.